BioCentury
ARTICLE | Clinical News

Trabedersen: Phase IIb data

November 15, 2010 8:00 AM UTC

An open-label, international Phase IIb trial in 134 evaluable patients with recurrent or refractory anaplastic astrocytoma or GBM showed that 10 µM trabedersen non-significantly improved tumor control...